Pacira Pharmaceuticals (PCRX) is an emerging specialty pharma company which in 2012 launched an opiate alternative (“Exparel”) for post surgical pain management. The product is currently approved for use in certain post surgical pain applications including removal of hemorrhoids and bunions. Since the product launch in April 2012, the shares have tripled, enjoying a boost…

Read More

Last week I published an article noting several sell signals which were emerging at Pacira Pharmaceuticals (PCRX), which was closing in on a triple since 2012. In just the past few weeks the shares have risen by more than 50%, to $30.00 from $20.00. Following my article, it was disclosed that MPM Asset Management, which employs both…

Read More